: Investigating approaches where patients only take the drug for a set period, especially if they achieve a complete response, to avoid unnecessary long-term exposure and side effects. If you'd like, I can:
: For those who stopped the medication, the median time until they did so was only 7 months . (616 KB)
The researchers analyzed a large group of 616 patients with who were treated with ibrutinib. The goal was to see if the high success rates found in clinical trials were mirrored in everyday medical practice across various hospitals. Key Findings and Statistics : Investigating approaches where patients only take the
The authors argue that because the drug is highly effective but often hard to tolerate, the medical community should focus on: The goal was to see if the high
: Both groups had roughly the same time (about 85–87 months) from their initial diagnosis until they started ibrutinib treatment. Clinical Implications
: A major finding was that 41% of patients stopped taking ibrutinib within a median of 17 months.
: Interestingly, the most common reason for stopping the drug was toxicity (intolerance) rather than the leukemia getting worse (disease progression).
: Investigating approaches where patients only take the drug for a set period, especially if they achieve a complete response, to avoid unnecessary long-term exposure and side effects. If you'd like, I can:
: For those who stopped the medication, the median time until they did so was only 7 months .
The researchers analyzed a large group of 616 patients with who were treated with ibrutinib. The goal was to see if the high success rates found in clinical trials were mirrored in everyday medical practice across various hospitals. Key Findings and Statistics
The authors argue that because the drug is highly effective but often hard to tolerate, the medical community should focus on:
: Both groups had roughly the same time (about 85–87 months) from their initial diagnosis until they started ibrutinib treatment. Clinical Implications
: A major finding was that 41% of patients stopped taking ibrutinib within a median of 17 months.
: Interestingly, the most common reason for stopping the drug was toxicity (intolerance) rather than the leukemia getting worse (disease progression).
